Class information for:
Level 1: METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
3703 1848 32.6 70%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
276 18466 BREAST CANCER//ACCELERATED PARTIAL BREAST IRRADIATION//PARTIAL BREAST IRRADIATION

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 METASTATIC BREAST CANCER Author keyword 162 31% 24% 439
2 VINORELBINE Author keyword 40 20% 10% 183
3 DOCETAXEL Author keyword 35 10% 18% 327
4 CAPECITABINE Author keyword 28 14% 10% 190
5 ADVANCED BREAST CANCER Author keyword 17 19% 4% 81
6 ANTHRACYCLINE RESISTANT Author keyword 15 88% 0% 7
7 NO ALBERTA BREAST CANC PROGRAM Address 14 100% 0% 7
8 ANTHRACYCLINE RESISTANCE Author keyword 12 50% 1% 17
9 DOCETAXEL TAXOTERER Author keyword 10 73% 0% 8
10 CANC THER Y DEV PROGRAM Address 6 80% 0% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 METASTATIC BREAST CANCER 162 31% 24% 439 Search METASTATIC+BREAST+CANCER Search METASTATIC+BREAST+CANCER
2 VINORELBINE 40 20% 10% 183 Search VINORELBINE Search VINORELBINE
3 DOCETAXEL 35 10% 18% 327 Search DOCETAXEL Search DOCETAXEL
4 CAPECITABINE 28 14% 10% 190 Search CAPECITABINE Search CAPECITABINE
5 ADVANCED BREAST CANCER 17 19% 4% 81 Search ADVANCED+BREAST+CANCER Search ADVANCED+BREAST+CANCER
6 ANTHRACYCLINE RESISTANT 15 88% 0% 7 Search ANTHRACYCLINE+RESISTANT Search ANTHRACYCLINE+RESISTANT
7 ANTHRACYCLINE RESISTANCE 12 50% 1% 17 Search ANTHRACYCLINE+RESISTANCE Search ANTHRACYCLINE+RESISTANCE
8 DOCETAXEL TAXOTERER 10 73% 0% 8 Search DOCETAXEL+TAXOTERER Search DOCETAXEL+TAXOTERER
9 ORAL VINORELBINE 5 33% 1% 13 Search ORAL+VINORELBINE Search ORAL+VINORELBINE
10 ADVANCED BREAST CARCINOMA 5 55% 0% 6 Search ADVANCED+BREAST+CARCINOMA Search ADVANCED+BREAST+CARCINOMA

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLINICAL SCREENING GROUP 103 97% 2% 30
2 WEEKLY IV VINORELBINE 88 89% 2% 40
3 INTRAVENOUS VINORELBINE 82 70% 4% 68
4 ANTHRACYCLINE RESISTANT 74 54% 5% 94
5 ANTHRACYCLINE PRETREATED PATIENTS 53 85% 2% 28
6 FIRST LINE CHEMOTHERAPY 51 50% 4% 74
7 FIRST LINE 46 59% 3% 51
8 LINE CHEMOTHERAPY 34 65% 2% 32
9 3 HOUR INFUSION 32 32% 4% 81
10 1ST LINE CHEMOTHERAPY 29 20% 7% 130

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Docetaxel - A review of its use in metastatic breast cancer 2005 81 55 78%
Vinorelbine in the management of breast cancer: New perspectives, revived role in the era of targeted therapy 2006 45 106 77%
Treatment of metastatic breast cancer: second line and beyond 2011 24 51 53%
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer 2011 16 166 72%
Chemotherapy of metastatic breast cancer: What to expect in 2001 and beyond 2001 106 73 74%
Capecitabine Monotherapy: Review of Studies in First-Line HER-2-Negative Metastatic Breast Cancer 2012 13 35 54%
Single agent versus combination chemotherapy for metastatic breast cancer 2009 33 44 61%
Management of Metastatic Breast Cancer Monotherapy Options for Patients Resistant to Anthracyclines and Taxanes 2010 20 40 65%
Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results 2012 8 26 73%
Gemcitabine in the management of metastatic breast cancer: a systematic review 2008 27 47 91%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NO ALBERTA BREAST CANC PROGRAM 14 100% 0.4% 7
2 CANC THER Y DEV PROGRAM 6 80% 0.2% 4
3 BREAST ONCOL GRP 3 57% 0.2% 4
4 BREAST CANC BIOL UNIT 3 60% 0.2% 3
5 BREAST CANC MED SERV 3 12% 1.1% 20
6 BERLIN BREAST CANC GRP 2 67% 0.1% 2
7 INVEST DRUG BRANCH BREAST CANC 2 67% 0.1% 2
8 SURG ONCOL A 2 40% 0.2% 4
9 BAYLOR SAMMONS CANC 2 16% 0.5% 10
10 ST CHIARA HOSP 1 38% 0.2% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000198861 HIGH DOSE CHEMOTHERAPY//DOSE INTENSITY//HIGH RISK BREAST CANCER
2 0.0000168734 NAB PACLITAXEL//CREMOPHOR EL//NEW MAT BIOL
3 0.0000145756 VINFLUNINE//VINCA ALKALOIDS//ONCOL PHARMACOKINET
4 0.0000129690 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
5 0.0000114311 NON COLORECTAL//STAGE IV BREAST CANCER//NON NEUROENDOCRINE
6 0.0000093103 PEGFILGRASTIM//FEBRILE NEUTROPENIA//FILGRASTIM
7 0.0000089834 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
8 0.0000085152 INFLAMMATORY BREAST CANCER//NEOADJUVANT CHEMOTHERAPY//LOCALLY ADVANCED BREAST CANCER
9 0.0000084718 VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER
10 0.0000073938 ORAL CHEMOTHERAPY//ORAL ANTICANCER AGENTS//ORAL ANTICANCER DRUGS